Fundraising Fox
/Companies
Sign in

Epana Bio

9 known investors

Find your way into Epana Bio

Sign up to see every warm intro you have to Epana Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Epana Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.

Also known as Epana

AI & Machine LearningBiotechDigital Health

Investors · 9

Breakout Ventureslisted by Breakout VenturesSan Francisco · $500K – $6M

How we know: Breakout Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

HAWKTAILlisted by HAWKTAILSan Francisco

How we know: HAWKTAIL's portfolio page · Not right? Tell us

Hummingbird Ventureslisted by Hummingbird VenturesBrussels · $500K – $10M

How we know: Hummingbird Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

OMX Ventureslisted by OMX VenturesLincolnshire

How we know: the VCSheet dataset · Not right? Tell us

Point Financial Capitallisted by Point Financial CapitalPhoenix · $500K – $40M

How we know: Point Financial Capital's portfolio page · Not right? Tell us

KdT VenturesreportedAustin · $500K – $3M

How we know: the VCSheet dataset · Not right? Tell us

Refactor CapitalreportedBurlingame · $1M – $2M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

South Park CommonsreportedSan Francisco · $1M – $10M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Company profile

researched Aug 2026

Epana Bio is a biotechnology company developing precision therapies for autoimmune disease. Its stated approach is to treat autoimmunity by targeting the cellular origin of disease rather than managing symptoms, with the goal of resetting the immune system. The company uses genomics and artificial intelligence to design treatments tailored to individual patients and to accelerate drug discovery.

The company operates in stealth mode and is headquartered in Berkeley, California, with an address on College Avenue; it is also associated with San Francisco through the South Park Commons community. It was founded by Danny Wells, described as an immunologist and data scientist. Its website articulates operating principles including a belief that small, focused teams can compete through nimbleness and pace of execution, and it advertises open positions and a general contact address.

Founding story

Epana Bio was founded by Danny Wells, an immunologist and data scientist, and appears in the South Park Commons company directory with a 2025 designation.

Traction

The company remains in stealth mode with no publicly disclosed products or clinical programs; it lists open positions on its website, though a South Park Commons listing shows no open roles.

▸Full profile — market position, technology, go-to-market, geography

Market position

Epana Bio is an early, seed-stage, stealth-mode biotechnology company positioned in precision medicine and AI-enabled drug discovery for autoimmune disease. Company-comparison listings group it with other biotechnology and drug-discovery companies such as Dren Bio, UCB and Cullinan Oncology.

Technology

Epana Bio applies genomics and artificial intelligence to identify and target the cellular origin of autoimmune disease and to design therapies tailored to individual patients. Descriptions of the company associate it with drug discovery approaches including targeted cell depletion, T-cell engagers (TCEs) and bispecific antibodies, and with in silico drug discovery.

Go-to-market

The company's stated focus is patients with autoimmune disease, for whom it aims to develop therapies designed specifically for them.

Geography

Headquartered in Berkeley, California (3036 College Avenue, Berkeley, CA 94705), with a San Francisco association through South Park Commons.

Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Funding stageJan 2025Seed
Operating statusJan 2025Stealth mode
Year foundedJan 20242024

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Related companies · 5

Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Triana BioTRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer. The company applies a target-first molecular glue discovery platform to pursue disease targets previously considered undruggable.
Jnana TherapeuticsJnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
AnaptysBioAnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders. It is a publicly traded biotech company running with fewer than ~10 contractors.
Arvinas Holding Co. LLCArvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

Companies working in the same space as Epana Bio.

▸Research sources · 7

primary sources listed

7 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Epana Bio do?
Epana Bio is a stealth-stage biotech developing precision therapies that target the cellular origin of autoimmune disease.
Who are Epana Bio's investors?
Epana Bio's investors include Breakout Labs, Breakout Ventures, HAWKTAIL, Hummingbird Ventures, OMX Ventures, Point Financial Capital, KdT Ventures, Refactor Capital and 1 more.